Tilray Inc. has obtained approvals from the New Zealand government to launch medical cannabis products across the country, according to the company’s press release. The company’s product offering in New Zealand approved under the scheme is centered on its Purified CBD products.
Tilray attributes the approval to the high standards the New Zealand Ministry of Health upholds for patients and the quality of Tilray’s medical cannabis products.
Company seeks to expand its product offering further and supply more patients in-need with high-quality medical cannabis products.
In addition to supplying hospitals and pharmacies, Tilray partners with several leading research institutions, including the Murdoch Children’s Research Institute in Australia.
Tilray stock is currently gaining. TLRY: NASDAQ is up 1.70%
